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Scott D. Solomon,MD, d Jean-Claude Tardif, MD, m YujunWu, PhD, h andMarc A. Pfeffer, MD, PhD d, for the ELIXA
InvestigatorsBoston, Brigham,MA;Houston, TX; Portland, OR; Santa Fe, Argentina; Stavenger, Norway; Ontario, Québec,
Canada; Bridgewater, NJ; Copenhagen, Denmark; Florence, Italy; Glasgow, United Kingdom; and Seattle, WABackground Cardiovascular (CV) disease is the leading cause ofmorbidity andmortality in patientswith type2 diabetesmellitus
(T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-
like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated.
Methods ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-
group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the
effects of lixisenatide on CV morbidity and mortality in a population at high CV risk. The primary efficacy end point is a
composite of time to CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Data are
systematically collected for safety outcomes, including hypoglycemia, pancreatitis, and malignancy.
Results Enrollment began in July 2010 and ended in August 2013; 6,068 patients from 49 countries were randomized. Of
these, 69% are men and 75% are white; at baseline, the mean ± SD age was 60.3 ± 9.7 years, body mass index was 30.2 ± 5.7
kg/m2, and duration of T2DMwas9.3±8.2 years. ThequalifyingACSwas amyocardial infarction in 83%and unstable angina in
17%. The study will continue until the positive adjudication of the protocol-specified number of primary CV events.
Conclusion ELIXA will be the first trial to report the safety and efficacy of a glucagon-like peptide 1 receptor agonist in
people with T2DM and high CV event risk. (Am Heart J 2015;169:631-638.e7.)neral Hospital, Boston,
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hThe increasing prevalence of type 2 diabetes mellitus
(T2DM) represents a significant public health concern
due to its cardiovascular (CV) and concomitant long-term
health consequences.1,2 Epidemiological studies have
demonstrated that patients with T2DM have both a 2- to
3-fold increased risk for the development of CV disease,1-3
and N60% of deaths are secondary to CV complications.4
Because patients with T2DM and acute coronary syn-
drome (ACS) are at particularly high risk for morbidity
and mortality despite modern therapies,5,6 the identifica-
tion of cardioprotective therapies is especially important.
The glucagon-like peptide 1 receptor agonists (GLP-1RAs)
are glucose-lowering agents that may have beneficial CV
effects.7 The US Food and Drug Administration (FDA)8 and
the European Medicines Agency9 have established guide-
lines for phase II/phase III clinical trials to ensure that new
therapies for diabetes are not associated with increased CV
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May 2015risk. These recommendations, prompted by adverse CV
effects of other glucose-lowering agents,10-12 specified
enrollment of high-risk participants, minimum treatment
exposure of 18 to 24 months, blinded central adjudication
of CV events, and sufficient number of events to exclude a
30% increase in risk. The ELIXA trial was designed to test the
efficacy and safety of the GLP-1RA, lixisenatide. In this
article, we describe the rationale for using lixisenatide, trial
design, and randomized patient characteristics.
Rationale
Glucose-lowering therapy and CV risk
Evidence-based primary and secondary CV risk reduction
strategies, such as the use of statins,13,14 angiotensin-
converting enzyme inhibitors, and β-blockers,15-17 are
effective in patients with T2DM. However, the role of
glycemic control in CV risk reduction is less clear. A
meta-analysis of clinical trials suggested that intensive
glycemic control in patients with T2DM reduced the risk of
nonfatal myocardial infarction (MI) but did not reduce total or
CV-related mortality.18 Furthermore, safety concerns about
glucose-lowering agents in patients with coronary heart
disease have been raised,19-21 and data demonstrate that
sulfonylureas inhibit protective ischemic preconditioning10,11
and thiazolidinediones and 1 dipeptidyl peptidase 4 (DPP-4)
inhibitor increase heart failure (HF) risk.12,22
Glucagon-like peptide 1 receptor agonists. Gluca-
gon-like peptide 1 (GLP-1) is a gastrointestinal hormone that
potentiates glucose-dependent insulin release and inhibits
glucagon secretion, thereby decreasing hepatic glucose
production, lowering basal and postprandial blood glucose,
and promoting weight loss by enhancing satiety. The
therapeutic utility of native GLP-1 is limited by its rapid
degradation by the enzyme DPP-4. Consequently, GLP-1RAs
were developed to retain many biological actions of native
GLP-1 while extending its half-life by preventing enzymatic
degradation. Glucagon-like peptide 1 receptor agonists
improve glycemic control with minimal hypoglycemia and
enhance weight loss.23,24
Lixisenatide is a once-daily GLP-1RA that lowers both
fasting and postprandial blood glucose.25 It has been
evaluated in the treatment of T2DM as monotherapy26 and
as add-on therapy with oral agents27 or basal insulins28-31
and both oral agents and basal insulins.29,32 Clinical trials
show that lixisenatide reduced glycated hemoglobin
(HbA1c) by 0.9% in monotherapy,26 0.8% to 0.9% in
combinationwith an oral agent,27 and 0.7%when added to
basal insulin and oral agent.29 Lixisenatide also reduced
weight27,33 and was associated with low risk of hypogly-
cemic events.34 Nonetheless, lixisenatide's long-term CV
safety and benefit in patients with T2DM and ACS have not
been established.
Acute coronary syndrome. Patients with an ACS and
T2DM are at a significantly increased risk for mortality,
recurrentMI, andHFcompared to thosewithoutT2DM.6,35,36Several factors may contribute to this diabetes-associated risk,
including concomitant conditions such as renal insufficiency
and hypertension, greater cardiac dysfunction, proinflamma-
tory and prothrombotic states, greater burden of atheroscle-
rosis, and detrimental effects of hyperglycemia and insulin
resistance.37,38 Because of the increasing prevalence of T2DM
and the greater risk of adverse outcomes in individuals with
T2DM and ACS, it is important to assess the CV effects of
glucose-lowering agents.
Methods
Study design and objectives
ELIXA (www.clinicaltrials.gov no. NCT01147250) is a
randomized, double-blind, placebo-controlled, paral-
lel-group, multicenter phase III event-driven trial de-
signed to assess the effects of lixisenatide added to
current T2DM therapy on CV morbidity and mortality in
patients with a recent ACS. The primary outcome is the
composite of CV death, nonfatal MI, nonfatal stroke, or
hospitalization for unstable angina (UA). Secondary trial
objectives include the examination of lixisenatide's
effects on composite end points including CV death,
nonfatal MI, nonfatal stroke, hospitalization for UA,
hospitalization for HF, or coronary revascularization.
Another trial objective is to assess the safety and
tolerability of lixisenatide in patients with T2DM and ACS.
Population recruitment
The inclusion and exclusion criteria are listed in Table I.
Patients with T2DM were identified and screened for a
spontaneous ACS within 180 days following the hospital
admission for the ACS but after discharge. Patients could
have T2DM diagnosed by World Health Organization
criteria before or after the qualifying ACS.39 Acute
coronary syndrome was defined as an ST-segment
elevation MI (STEMI), non-STEMI, or UA. The clinical
presentation required admission to an acute care facility
and elevation of a cardiac biomarker (troponin or creatine
kinase-MB isoenzyme [CK-MB]) above the reference range
for MI or intermediate range for UA.
Randomization and study treatment
Eligible patients entered a run-in period of 7 (+3) days
(online Appendix A). Patients were trained in self-
administration of daily subcutaneous injections of volu-
me-matched placebo (equivalent to 10 μg/d lixisenatide).
At the end of the run-in period, eligible patients were
randomized 1:1 to lixisenatide or volume-matched placebo
for the double-blinded study treatment. In accordancewith
protocol (online Appendix B), the dose could be down- or
up-titrated to a maximum of 20 μg/d in the absence of
symptoms, such as hypoglycemia or gastrointestinal
distress. Glycemic control will be managed according to
the best judgment of site investigators and informed by
clinical practice guidelines. Adjustment of background and
Table I. ELIXA inclusion and exclusion criteria
Inclusion criteria
1. Spontaneous ACS defined as STEMI, non-STEMI, or UA
• Presentation for ACS leading to acute care facility admission AND
• Elevated cardiac biomarker (troponin or creatine kinase-MB)
above ULN⁎ AND
• Screening within 180 days following the hospital admission for the
ACS but after discharge
2. Type 2 diabetes history or newly diagnosed defined
by World Health Organization criteria: fasting venous
PG ≥7.0 mmol/L (126 mg/dL) or 2-h postglucose load
venous PG ≥11.1 mmol/L (200 mg/dL),
confirmed on 2 occasions
3. Informed written consent
Exclusion criteria
1. Age b30 y
2. Type 1 diabetes
3. History of metabolic acidosis, including diabetic
ketoacidosis within 6 m
4. Use of incretin-based agents other than study agent
5. History of unexplained pancreatitis,
chronic pancreatitis, pancreatectomy,
stomach/gastric surgery, inflammatory bowel disease,
personal or family history of medullary thyroid cancer,
or genetic conditions that predispose to
medullary thyroid cancer
6. Planned revascularization procedure
(PCI or coronary artery bypass graft) or coronary
angiogram within 90 d after screening or randomization
7. PCI within 15 d
8. Women who are pregnant, lactating,
or of childbearing potential without contraception
9. Clinically relevant history of gastrointestinal disease
associated with prolonged nausea and vomiting
10. Laboratory data at screening (1 retest within 1 wk
of result receipt is permitted and second result is decisive):
• HbA1c b5.5% or N11%
• Amylase and/or lipase N3× ULN
• Calcitonin N20 pg/mL (5.9 pmol/L)
• Alanine transaminase N3× ULN or total bilirubin N1.5× ULN
(excluding Gilbert disease)
• Estimated glomerular filtration rate b30 mL/min/1.73 m2
• Hemoglobin level b10 g/dL and/or neutrophils b1500/mm3
and/or platelets b100,000/mm3
Abbreviation: PG, Plasma glucose.
⁎ Intermediate range troponin for UA.
Table II. ELIXA end points
ime to first occurrence of any of the following composite
nd points adjudicated and validated by the CAC
rimary
• CV death
• Nonfatal MI
• Nonfatal stroke
• Hospitalization for UA
econdary
• Primary end points (as defined in A.) or hospitalization for HF
• Primary endpoints (as defined in A.) or hospitalization
for HF or coronary revascularization procedure
• Percent change in the urinary albumin/creatinine ratio
from baseline to 108 wk
dditional end points
• Cardiometabolic markers: glycated hemoglobin,
fasting plasma glucose, high-sensitivity C-reactive protein,
BNP, N-terminal proBNP
• Body weight
• Patient reported outcomes
• The Seattle Angina questionnaire
• The Diabetes Health Profile-18
• Euroqol EQ-5DThe McMaster Overall Treatment Evaluation
bbreviations: CAC, CV events adjudication committee; BNP, B-type natriuretic peptide.
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Volume 169, Number 5investigational drug treatment will be permitted, as is the
prescription of other glucose-lowering medications, exclud-
ing GLP-1RAs and DPP-4 inhibitors (online Appendix B).
End points and safety assessment
The ELIXA end points are listed in Table II and defined in
online Appendix C. In addition to analysis of all reported
adverse events, hypoglycemia will be systematically
assessed at each visit. Symptomatic hypoglycemia was
defined as symptoms consistent with hypoglycemia, blood
glucose b60 mg/dL (3.3 mmol/L), and/or prompt recovery
after treatment. Severe hypoglycemia was defined as
symptomatic hypoglycemia requiring assistance by
another person, blood glucose b36 mg/dL (2.0 mmol/L),T
e
P
S
A
Aand/or prompt recovery after treatment. Prespecified
safety end points will be monitored, including local
injection site or allergic reactions and suspected pancrea-
titis or pancreatic cancer.
Statistical analysis
Sample size determination. Recruitment of 6,000
patients was projected to occur over 37 months with at
least 10 months of follow-up for the last randomized
patient. This event-driven study was designed to continue
until 844 positively adjudicated events for the primary
composite CV end point occurred, assuming a 10%
annual event rate for the first year and a 7% annual event
rate subsequently. This prespecified number of events
was estimated to provide 96% power to demonstrate
noninferiority of lixisenatide over placebo with the 1.3
noninferiority boundary, assuming a true risk ratio (RR) of
1.0, and 90% power to demonstrate superiority of
lixisenatide over placebo, assuming a RR of 0.80.
Primary end point analyses. The primary efficacy
analysis will be performed according to the intent-to-treat
principle. All randomized patients will be followed up to
the end of study for all nonfatal outcomes. The time to the
first occurrence of the primary composite CV end point
will be analyzed using a Cox proportional hazards model
with treatment (lixisenatide and placebo) and geographical
region as fixed-effect factors. Treatment effects across
subgroups of gender, age, race, and duration of T2DMwill
be examined similarly. The HR and 2-sided 95%CI between
lixisenatide and placebo will be estimated. Noninferiority
of lixisenatide versus placebo will be established if the
Table III. Baseline characteristics of randomized population (n = 6068)
Age, y, mean ± SD 60.3 ± 9.7
Age ≥65 y 2043 (33.7)
Male 4207 (69.3)
Race
Asian 768 (12.7)
Black 221 (3.6)
White 4563 (75.2)
Other 516 (8.5)
Ethnicity
Hispanic 1768 (29.1)
BMI, kg/m2, mean ± SD 30.2 ± 5.7
18.5-24.9 1017 (16.8)
25.0-29.9 2297 (37.9)
≥30 2734 (45.1)
Cholesterol, mg/dL, mean ± SD⁎
Total 153 ± 44
Triglycerides 164 ± 113
High-density lipoprotein 43 ± 11
Low-density lipoprotein 78 ± 35
Fasting plasma glucose, mg/dL, mean ± SD† 148 ± 52
HbA1c, %, mean ± SD 7.7 ± 1.3
Days between qualifying ACS and screening, mean ± SD 64.0 ± 43.6
b30 1462 (24.1)
≥30 to b60 1959 (32.3)
≥60 2643 (43.6)
Days between qualifying ACS and randomization, mean ± SD 72.0 ± 43.6
b30 796 (13.1)
≥30 to b60 2184 (36.0)
≥60 3084 (50.9)
Qualifying ACS event
STEMI 2667 (44.0)
Non-STEMI 2346 (38.7)
UA 1042 (17.2)
ACS intervention
Percutaneous coronary intervention 3741 (61.7)
Coronary artery bypass graft 41 (0.7)
Thrombolytic 476 (7.8)
Smoking
Current 707 (11.7)
Former 2744 (45.2)
Diabetes duration, y, mean ± SD 9.3 ± 8.3
Retinopathy 648 (10.7)
Neuropathy 1050 (17.3)
Estimated glomerular filtration rate (mL/min/1.73 m2), mean ± SD 76.0 ± 21.3
b30 8 (0.1)
30-60 1398 (23.1)
60-90 3228 (53.4)
≥90 1413 (23.4)
Baseline albumin/creatinine ratio (mg/g)
b30 4434 (74.3)
30-300 1146 (19.2)
≥300 389 (6.5)
Data presented are number (pecentages) unless otherwise indicated. Percentages are calculated based on the number of patients with available data. Abbreviation: BMI, Body mass index.
⁎SI units (mmol/L) = mg/dL * 0.0259.
†SI units (mmol/L) = mg/dL * 0.0555.
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accordance with the FDA's requirement to confirm CV
safety of lixisenatide. Next, the superiority of lixisenatide
over placebo will be established if the upper bound of the
2-sided 95% CI of the HR is b1.0. The P value will be
calculated using the log-rank test for descriptive purposes.Study organization and leadership
ELIXA was designed and will be managed by an
executive committee comprising clinical experts in
both cardiology and diabetes who are based in academic
medical centers and sponsor representatives with clinical
and methodological expertise in diabetes and clinical
Table IV. Baseline CV and diabetes medications
CV medications
ACEI 3658 (60.3)
ARB 1604 (26.4)
ACE or ARB 5151 (84.9)
β-Blocker 5119 (84.4)
Diuretic 2015 (33.2)
Mineralocorticoid receptor antagonist 870 (14.3)
Calcium-channel blocker 1327 (21.9)
α1-Blocker 277 (4.6)
Hydralazine 51 (0.8)
Renin inhibitor 19 (0.3)
Nitrates 1541 (25.4)
Other antianginal 435 (7.2)
Aspirin 5726 (94.4)
Any thienopyridine 4495 (74.1)
Vitamin K antagonist 279 (4.6)
Factor Xa inhibitor 22 (0.4)
Other anticoagulant 480 (7.9)
Statin 5621 (92.6)
Ezetimibe 97 (1.6)
Fibrate 247 (4.1)
Nicotinic acid and derivatives 62 (1.0)
Digitalis glycoside 137 (2.3)
Amiodarone 139 (2.3)
Other antiarrhythmic 36 (0.6)
Other CV medications 125 (2.1)
Diabetes medications
Any diabetes medications 5440 (89.7)
Metformin 3834 (63.2)
Sulfonylurea 1863 (30.7)
Glinide 71 (1.2)
Thiazolidinedione 84 (1.4)
Insulin 2292 (37.8)
Combination insulin and oral agent 1368 (22.5)
Combination metformin and sulfonylurea 1329 (21.9)
Other diabetes medications 329 (5.4)
Data presented are number (pecentages). Abbreviations: ACEI, Angiotensin-converting
enzyme inhibitor; ARB, angiotensin receptor blocker.
Table V. Cardiovascular and diabetes history (n = 6068)
oronary heart disease
Stable angina pectoris 1313 (21.6)
UA pectoris 742 (12.2)
MI 1340 (22.1)
Percutaneous coronary intervention 1000 (16.5)
Coronary artery bypass graft 479 (7.9)
erebrovascular disease
Stroke 314 (5.2)
Transient ischemic attack 135 (2.2)
Carotid artery stenosis (≥50%) 137 (2.3)
Carotid endarterectomy 35 (0.6)
Carotid artery stent insertion 34 (0.6)
Carotid artery bypass 8 (0.1)
eripheral artery disease 365 (6.0)
ardiac arrhythmia
Atrial fibrillation or flutter 282 (4.6)
Ventricular fibrillation or tachycardia 66 (1.1)
ther CV history
Hypertension 4581 (75.5)
Valvular heart disease 166 (2.7)
Implantable cardioverter defibrillator 41 (0.7)
Cardiac resynchronization therapy 8 (0.1)
Conventional pacemaker 65 (1.1)
Chronic HF 750 (12.4)
Other 507 (8.4)
Data presented are before qualifying ACS event and are number (percentages).
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Volume 169, Number 5trials. The executive committee will assume responsibil-
ity for data integrity and interpretation, study content,
and the primary manuscript. Additional committees
established to ensure trial integrity as well as study drug
safety and tolerability include a data monitoring commit-
tee consisting of members independent from the
executive committee and sponsor to monitor patient
safety; a CV event adjudication committee to evaluate and
adjudicate, in a blinded fashion, all potential end points; a
glycemia committee composed of endocrinologists to
provide glycemic control support for site investigators
and to ensure patient safety from hypoglycemia; an
allergic reaction assessment committee composed of
clinical immunologists independent of the sponsor and
investigators and blinded to study treatment to assess
allergic or allergic-like reactions; and a pancreatic safety
assessment committee to review all pancreatic adverse
events, including suspected pancreatitis and pancreatic
cancer (online Appendix D).C
C
P
C
OELIXA was approved by the appropriate institutional
or central review boards. All trial participants provided
written informed consent. This study was sponsored
solely by Sanofi, and the authors were solely responsible
for study design. The authors will be solely responsible
for completion of the final manuscript, and statistical
analyses (performed by the academic statistician and
validated by the sponsor's statistician).
Results
Screening and enrollment into ELIXA began June 24,
2010, and randomization was completed on August 2,
2013. There were 7,718 candidates screened and 6,068
participants randomized to either lixisenatide or placebo
(online Appendix A) from 49 countries across 6 regions
(online Appendix E) with the support of 782 principal
investigators (online Appendix F). One additional candi-
date was screened and randomized but excluded from
analysis due to inadequate consent. Baseline data include
data available and validated as of June 29, 2014.
Baseline clinical characteristics of the randomized
population are shown in Table III. The mean ± SD age
was 60.3 ± 9.7 years, 69.3% were male, and 75.2% were
white. The index ACS events were STEMI (44.0%),
non-STEMI (38.7%), and UA (17.2%). The mean ± SD
duration between qualifying ACS and screening was
64.0 ± 43.6 days, and 61.7%of individuals had a percutaneous
coronary intervention (PCI) after their ACS. The mean ± SD
duration of T2DM was 9.3 ± 8.3 years, HbA1c was 7.7% ±
636 Bentley-Lewis et al
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May 20151.3%, and prevalence of obesity (BMI≥30 kg/m2) was 45.1%.
Statin therapy was used by 92.6% of participants, and 37.8%
were taking insulin (Table IV). Relevant CV and diabetic
history before the qualifying ACS event is provided in Table V.Discussion
ELIXA will determine the effects of lixisenatide, a
GLP-1RA, compared to placebo on the burden of CV
disease in patients with T2DM and ACS. Although native
GLP-1 and GLP-1RAs exert favorable CV effects in animal
models of MI and ischemia/reperfusion injury,40-42 few
data exist in humans. In small placebo-controlled studies,
GLP-1RA treatment improved myocardial salvage and
reduced infarct size.43,44 A larger retrospective analysis
revealed that the nonrandomized use of GLP-1RA was
associated with a 19% lower CV event risk compared with
other glucose-lowering agents.45 In addition, a meta-
analysis revealed a significant reduction in CV events
among individuals taking GLP-1RAs rather than placebo
or other glucose-lowering agents.46 Therefore, ELIXA has
been designed and powered to verify the CV safety of
lixisenatide by demonstrating FDA-mandated noninferi-
ority to placebo and to assess superiority in CV outcomes
once noninferiority has been established.
To date, prior randomized CV studies of glycemic
agents have demonstrated mixed and, sometimes,
unexpected results. In the PROactive study, the thiazo-
lidinedione, pioglitazone, reduced the secondary com-
posite end point of nonfatal MI, stroke, and death but was
associated with increased HF events.47 Although a
meta-analysis suggested rosiglitazone increased ischemic
events, the RECORD trial demonstrated no effect on CV
events or mortality, although HF events were increased.48
Recently, CV trials of the DPP-4 inhibitors, saxagliptin
(SAVOR-TIMI 53)49 and alogliptin (EXAMINE),50 demon-
strated noninferiority compared to placebo for primary
CV efficacy end points, but superiority was not demon-
strated. Notably, an increase in HF hospitalizations was
observed with saxagliptin.49 A phase III clinical trial of
aleglitazar, a combined peroxisome proliferator-activated
receptor-α/γ agonist (ALECARDIO), was halted due to
safety and efficacy concerns, despite favorable effects on
HbA1c and lipids.51 Finally, a pragmatic design CV
outcome trial (TECOS) is currently investigating the CV
safety of the DPP-IV inhibitor, sitagliptin, in more than
14,000 patients with T2DM and vascular disease.52 These
studies highlight the importance of CV outcome trials in
patients with T2DM.
Several trials are ongoing or planned to investigate the
safety and efficacy of GLP-1RAs in patients with high CV
risk (online Appendix G). LEADER, a phase IIIB placebo-
controlled trial, is evaluating the CV safety of liraglutide in
patients with T2DM.53 In addition, studies of exenatide,
dulaglutide, and semaglutide will focus on patients
with T2DM and either established or high risk for CVdisease. ELIXA will be the first to report long-term CV
outcomes of a GLP-1RA in patients with T2DM and recent
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Volume 169, Number 5Appendix A. ELIXA trial designAppendix B. Guidance for protection
against hypoglycemia
• For patients with a screening HbA1c b8.5% and treated
with either insulin, glinide, or a sulfonylurea (SU), the
dose should be decreased at baseline (visit 2, randomization).
The following guidance should be applied:
− For SU or glinide, decrease the dose by 25% to 50%
(or discontinue in case of minimum dose).
− For insulin, decrease the total dose by 20%.
• After randomization, SU, glinide, or insulin dose can be
adjusted at the investigator's discretion.n Suggestive characteristics are presentation with acute ischemic
ymptoms and electrocardiographic changes indicative of an acute
jury or abnormal cardiac biomarkers or other evidence (eg,
chocardiography, ventriculography, or scintigraphy) of new
entricular wall motion abnormality.Appendix C. ELIXA end point definitions
Appendix C.1. Cardiovascular death
Appendix C.1.1. Fatal MI.
a. Death occurring within 14 days after a documented
MI, in which there is no conclusive evidence of any
other cause of death. Subjects who are being treated
for a MI and who die as a result of complications of
the MI (eg, sudden death, pump failure, or cardiogenicshock) will be classified as having had an
MI-related death
OR
b. Autopsy evidence if a recent infarct with no conclusive
evidence of any other cause of death.
OR
c. An abrupt death that has characteristics suggestiven of
an acute infarct but do not meet the strict definition of
an MI.
Appendix C.1.2. Pump failure. Death occurring in
the context of clinically worsening symptoms and/or signs
of HF without evidence of another cause of death.
Death occurring after the implementation of a ventricular
assist device or after surgery primarily for refractory HF.s
in
e
v
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May 2015Death occurring after referral to hospice specifically for
progressive HF.
Note: If worsening HF is secondary to MI,
then MI should be listed as the primary cause
of death if the subject had an MI within 14 days
of death (as above).
Appendix C.1.3. Sudden death. Death occurring
unexpectedly in an otherwise stable subject.
Further subclassification:
(1) death witnessed or subject last seen alive b1 hour
previously or
(2) subject last seen alive≥1 hour and b24 hours previously
Appendix C.1.4. Presumed sudden death. Death
occurring unexpectedly in an otherwise stable subject
last seen alive 24 hours previously with circumstances
suggestive of sudden death.
Appendix C.1.5. Presumed CV death. Death likely
due to a CV cause in which the available clinical data are
insufficient to support a more specific cause of death.
Appendix C.1.6. Fatal stroke.
a. Ischemic stroke. Death occurring as a result of
documented ischemic stroke.
b. Hemorrhagic stroke. Death occurring as a direct
result of documented hemorrhagic stroke.
c. Clinical stroke. Death occurring as a direct result
of documentation based on clinical circumstances
and identified as unknown type stroke.o Hospitalization is defined as admission to an acute care facility
(ie, hospital, emergency department, observation unit) with a
change in calendar day from hospital presentation to discharge.Appendix C.1.7. Fatal pulmonary embolism.Death
occurring as a direct result of documented pulmonary
embolism.
Appendix C.1.8. Procedure-related death. Death
occurring during a CV procedure-related death or as a
result of procedure-related complications (usually within
14 days of the CV procedure).
Appendix C.1.9. Other CV death. Death resulting
from a specifically documented CV cause other than
those listed above.
Appendix C.2. Non-CV death
If an unequivocal and documented non-CV cause can
be established as the primary cause of death, the event
will be classified as non-CV. Non-CV deaths will be further
classified into the following categories:
A. Infection
B. Malignancy
C. Pulmonary
D. GastrointestinalE. Renal
F. Accidental
G. Suicide
H. Diabetes related
I. Other non-CV (specify)
Appendix C.3. Unknown death
Death in which insufficient data are available to make a
reasonable differentiation between CV and non-CV causes
of death.
Appendix C.4. Nonfatal end point definitions
The CV events adjudication committee will receive for
review and adjudicate all occurrences of the following
nonfatal end points:
1. Hospitalization for HFo
2. Myocardial infarction
3. Hospitalization for UA†
4. Stroke
5. Coronary revascularization
1. Hospitalization for HF
Unplanned presentation to an acute care facility for an
exacerbation of HF requiring an overnight stay (change in
calendar day) which meets the following criteria (I-III):
I. Symptoms of HF:
At least 1 of the following:
a. Worsening dyspnea
b. Worsening orthopnea
c. Paroxysmal nocturnal dyspnea
d. Increasing fatigue/worsening exercise tolerance
II. Signs of HF:
At least 2 of the following:
a. Rapid weight gain
b. Pulmonary edema or rales
c. Elevated jugular venous pressure
d. Radiologic signs of HF
e. Peripheral edema
f. Increasing abdominal distension or ascites
g. S3 gallop
h. Hepatojugular reflux/hepatomegaly
i. Elevated BNP or NT-pro-BNP
III. Treatment for HF:
At least 1 of the following:
a. Treatment with intravenous diuretics, vasodila-
tors, or inotropes.
b. Mechanical fluid removal (eg, ultrafiltration or
dialysis).
c. Insertion of an intraaortic balloon pump for
hemodynamic compromise.
d. Initiation of oral diuretics or intensification of
the maintenance oral diuretic dose.
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Summary criteria for positive adjudication:
○ Spontaneous MI: Elevated cardiac markers (CM) and
either new electrocardiographic (ECG) changes or a
clinical presentation consistent with an acute MI.
○ PCI-related MI: Elevated CM (or other criteria in the
absence of elevated CM).
○ Coronary artery bypass graft (CABG)–related MI:
Elevated CM and new ECG changes (or other criteria).
Detailed criteria for positive adjudication:
a. Spontaneous MI:
Cardiac markers:
○ Troponinp Nupper limit of normal (ULN) or
○ CK-MB NULN
and at least 1 of the following:
○ Ischemic symptoms: rest or accelerated symptoms
(pain, dyspnea, and pressure) consistent with
myocardial ischemia.
○ ECG changes consistent with infarction:
• New significant Q waves (or R waves in V1-V2) in
2 contiguous leads in absence of previous left ventricular
hypertrophy or conduction abnormalities. OR
• Evolving ST-segment to T-wave changes in ≥2 contig-
uous leads.
• Development of new left bundle-branch block.
• ST-segment elevation requiring thrombolytics or PCI.
b. PCI-related MI:
Cardiac markersq:
1. Assuming baseline value bULN
2. Within 48 hours of procedure
a. Troponinp N3× ULN OR
b. CK-MB N3× ULN
c. CABG-related MI:
Cardiac markers:
1. Assuming baseline value bULN
2. Within 72 hours of procedure
a. Troponinp N5× ULN OR
b. CK-MB N5× ULN
AND
c. New pathologic Q waves or left bundle-branch block,
new native or graft vessel occlusion, or imaging
evidence of loss of viable myocardium.
3. Hospitalization for UA
a. Unplanned hospitalization for worsening angina
defined as rest or accelerated symptoms (pain,p If troponin given in ranges, the ULN for MI will be the lowest
value in the necrosis range.
q In the absence of cardiac markers, new pathologic Q waves that
are persistent upon discharge or documentation of new wall motion
abnormality (other than septal) will also meet criteria.dyspnea, and pressure) consistent with myocardial
ischemia AND
b. Cardiac markers (CK-MB or troponin) suggestive of
myocardial injury but not meeting MI criteria.
Note: if abnormal troponin, value must be in the suggestive
(middle) range and below the threshold for MI.
4. Stroke:
Stroke is defined as one of the following (1-4):
1. A new, focal neurologic deficit of central
origin lasting N24hours, irrespective of imaging
findings.
2. A new, focal neurologic deficit of central
origin lasting b24 hours with imaging evi-
dence of new cerebral infarction or intrace-
rebral hemorrhage consistent with the
reported deficits.
3. A new, focal neurologic deficit of central origin
lasting b24 hours that was treated with throm-
bolytic therapy or directed percutaneous
intervention.
4. A new, nonfocal encephalopathy lasting N24
hours with imaging evidence of cerebral
infarction or hemorrhage adequate to account
for the clinical state.
Note: retinal artery ischemia or hemorrhage is included in
the definition of stroke.
Classification:
Stroke will be further classified as follows:
a. Ischemic stroke: stroke with imaging suggesting
ischemic changes
b. Ischemic stroke with hemorrhagic conversion:
stroke with evidence of hemorrhage on imaging,
judged to be hemorrhagic transformation of a
primary ischemic stroke.
c. Primary intracranial hemorrhage: stroke with
evidence on imaging of intracerebral hemorrhage
not due to a transformation of an ischemic stroke.
d. Unknown: imaging is unavailable or inconclusive.
5. Coronary revascularization
Urgent coronary revascularization is defined as
nonelective coronary revascularizationr (PCI or CABG)
for themanagement of ACS (hospitalization formyocardial
ischemia,UA, orMI) performedas soonas canbe arranged.
Nonurgent revascularization is any PCI or CABG not
meeting criteria for urgent revascularization.r Note for PCI: includes balloon angioplasty (or PTCA), coronary
stenting, atherectomy, brachytherapy, laser, and rotational ablation.
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Appendix D.1. Executive committeeAppendix E. Randomized participants
Marc A. Pfeffer, MD, PhD (Chair) United States
Rafael Diaz, MD Argentina
Kenneth Dickstein, MD Norway
Hertzel Gerstein, MD Canada
Lars Køber, MD Denmark
Eldrin Lewis, MD United States
Aldo Maggioni, MD Italy
John McMurray, MD United Kingdom
Jeffrey Probstfield, MD United States
Matthew Riddle, MD United States
Region n (%)
United States and Canada 807 (13)
Central and South America and Mexico 1944 (32)
Eastern Europe 1587 (26)
Asia and Pacific islands 703 (12)
Africa/Near East 296 (5)
Western Europe 731 (12)
Christopher Granger, MD (Chair) United States
Jean Rouleau, MD Canada
David DeMets, PhD United States
Nishi Chaturvedi, MD United Kingdom
Denis Raccah, MD (non-voting) FranceAppendix D.2. Cardiovascular events adjudication
committee
Scott D. Solomon, MD (Chairman)
Eldrin F. Lewis, MD (Co-Chairman)
Ebrahim Barkoudah, MD
Rhonda Bentley-Lewis, MD
Abdel Brahimi, MD
David Charytan, MD
Peter Finn, MD
Aiden Flynn, MD
L. Howard Hartley, MD
Galen Henderson, MD
Jacob Joseph, MD
Kayode Odutayo, MD
Vinutha Rajesh, MD
Ali Vazir, MD
Larry Weinrauch, MD
Appendix D.3. Glycemia committee
Scott Solomon, MD United States
Jean-Claude Tardif, MD CanadaMatthew Riddle, MD (Chair) United States
Rhonda Bentley-Lewis, MD United StatesAppendix D.4. Allergic reaction assessment committee
Stefano del Prato, MD Italy
John Petrie, MD United KingdomAllen Kaplan, MD (Chair) United States
Phil Lieberman, MD United StatesAppendix D.5. Pancreatic safety assessment committee
Bruce L. Zuraw, MD United StatesEileen O’Reilly, MD (Chair) United States
Keyur Patel, MD (Co-Chair) United States
Peter Allen, MD United States
Aldo Scarpa, MD Italy
Mark Schattner, MD United StatesAppendix D.6. Data monitoring committeeby regionAppendix F. ELIXA participating countries
(no. of patients) and principal investigators
Argentina (399): Aizenberg, Diego; Alvarez, Carlos;
Alvarisqueta, Andres; Baccaro, Claudia; Bartolacci, Ines;
Bordonava, Anselmo; Bustamante Labarta, Miguel; Caccavo,
Alberto; Calella, Pedro; Cantero, Maria; Codutti, Renzo;
Commendatore, Victor; Costamagna, Osvaldo; Cuello, Jose;
Fernandez, Alberto; Garcia Duran, Ruben; Gomez Vilamajo,
Oscar; Gorban de Lapertosa, Silvia; Grinfeld, Diego;
Hermida, Sonia; Lagrutta, Mariana; Leon de la Fuente,
Ricardo; Licheri, Alberto; Luciardi, Hector; Mackinnon,
Ignacio; Maffei, Laura; Marino, Javier; Montaña, Oscar;
Novaretto, Leonardo;Orio, Silvia;Orlandini, Andres;Oviedo,
Alejandra; Pérez Manghi, Federico; Patocchi, Cristian;
Ramos, Hugo; Rolandi, Florencia; Saa Zarandon, Raquel;
Saavedra, Silvia Salome; Schiavi, Lilia; Schygiel, Pablo; Trivi,
Marcelo; Ulla, Maria; Urdiales, Pedro; Vallejos, Julio; Vico,
Marisa; Waisman, Florencia. Australia (17): Amerena, John;
Paul, Vincent; Sangla, Kunwarjit; Van Gaal, William; Yeap,
Bu. Austria (4): Fasching, Peter; Pieber, Thomas. Belarus
(34): Danilova, Larisa; Mitkovskaya, Natalya; Sudzhaeva,
Svetlana. Belgium (15): Mathieu, Chantal; Pouleur, Anne--
Catherine. Brazil (448): Botelho, Roberto Vieira; Cerqueira,
Maria Jose; Chacra, Antonio; Dos Santos, Fabio; Feitosa,
Gilson; Forti, Adriana; Golbert, Milton; Halpern, Alfredo;
Hissa, Miguel; Lisboa, Hugo; Moraes Junior, Joao; Nery, Max;
Quadros, Alexandre; Raduan, Roberto; Reis, Gilmar; Ribeiro
Filho, Fernando; Rollin, Guilherme; Rossi, Paulo; Santos,
Elizabete; Sgarbi, Jose; Souza, Juliana; Souza, Maria Regina.
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Neli; Kyoleyan, Michael; Levterov, Georgi; Lucheva, Mariya;
Raev, Dimitar; Shumkova, Rositsa; Tokmakova, Mariya;
Tzekova, Maria; Yordanov, Viktor. Canada (111): Bailey,
Gordon; Bertrand,Olivier; Bhargava, Rakesh; Burton, Jeffrey;
Campeau, Jean; Dumas, Richard; Filteau, Pierre; Syan,
Gurcharan; Syan, Rajinder; Tardif, Jean-Claude; Tsoukas,
George; Warnica, James Wayne. Chile (246): Acuña, Silvia;
Araneda, Guillermo; Bunster, Lia; Cobos, Leonardo; Corba-
lán, Ramón; Dussaillant, Gaston; Eggers, German; Floren-
zano, Fernando; Godoy, Gonzalo; Huidobro, Laura Andrea;
Lahsen, Rodolfo; Lanas, Fernando; Larenas, Gladys; Manri-
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Victor; Sanhueza, Patricio; Sepulveda, Pablo; Solis, Carmen
Lia; Soto, Nestor; Torres, Claudia; Westerberg, Bernhard;
Yañez, Mario. China (113): Chen, Li; Dong, Yugang; Du,
Jianling; Guo, Xiaohui; Han, Ping; Hu, Taohong; Jiang, Bin;
Ke, Yuannan; Li, Zhanquan; Lu, Juming; Ma, Changsheng;
Peng, Yongde; Shi, Yongquan; Su, Guohai; Tang, Baopeng;
Xu, Biao; Yang, Jiefu; Yang, Jinkui; Yang, Yanmin. Colombia
(265): Accini, Jose Luis; Arteaga, Juan Manuel; Botero,
Rodrigo; Castillo, Gilberto; Coronel, Julian; Cure, Carlos;
Garcia, Henry; Garcia, Luis; Gomez, Claudia; Hernandez
Triana, Eric; Hernandez, Hector; Lopez, Monica; Lopez,
Patricio; Manzur, Fernando; Molina, Dora; Rodriguez, Jaime;
Sanchez Vallejo, Gregorio; Yupanqui, Hernan. Denmark
(54): Bronnum-Schou, Jens; Kaiser Nielsen, Peter; Nielsen,
Henrik; Rønne, Henning; Rasmussen, Soeren; Rungby,
Jørgen; Skagen, Knud; Thomsen, Kristian Korsgaard;
Torp-Pedersen, Christian. Ecuador (27): Duarte-Vera, Yan;
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(6): Assaad, Samir; Shelbaya, Salah. Estonia (52): Ambos, Anu;
Jakovlev, Ulle; Lubi, Maire; Märtsin, Kaja; Rosenthal, Svea;
Vides, Hella. Finland (44): Alanko, Juha; Korsoff, Pirkko;
Koski, Anna-Mari; Lahtela, Jorma; Nelimarkka, Lassi; Tuomi-
lehto, Jaakko. France (38): Cariou, Bertrand;Catargi, Bogdan;
Ducloux, Roxane; Hadjadj, Samy; Kerlan, Veronique;
Malecot, Jean-Marc; Petit, Catherine; Rodier,Michel. Georgia
(58): Chumburidze, Vakhtang; Glonti, Salome; Lominadze,
Zaza; Todua, Fridon. Germany (96): Contzen, Christel; Dr.
Marck, Cornelia; Fischer, Hermann; Hagenow, Andreas;
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